ID: MRFR/Pharma/2003-HCR | 84 Pages | Published By Kinjoll Dey on March 2023
The Nasal Drug Delivery Market is touted to reach USD 79.4 Billion at CAGR of 7.50 % by the end of 2020-2030.
$79.4 Billion
7.50%
North America
2022-2030
The nasal drug delivery market was valued at USD 52,998.5 million in 2018 and is projected to reach USD 79.4 Billion at 7.50% CAGR during the forecaast period 2022-2030.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. Â
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.Â
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. Â
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.By Drug Type
By Dosage Form
By Basis of System
By Delivery Technologies
By Application
By End User
By Region
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | 79.4 Billion |
CAGR | 7.50% |
Base Year | 2019 |
Forecast Period | 2030 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Drug Type, Dosage Form, Basis of System, Therapeutic Applications, End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) |
Key Market Opportunities | The Increasing number of patient population |
Key Market Drivers | Factors such as the painless drug administration, development of new technological nasal drug delivery devices |
Nasal drug delivery market projected to grow at approximately 7.50% CAGR during the assessment period (2020-2030).
Nasal drug delivery market had valued at around USD 52,998.5 MN in 2018.
Development of new technological nasal drug delivery devices and the increasing number of patient population with respiratory problem, are major tailwinds pushing the growth of the global nasal drug delivery market.
North America holds the largest share in the global nasal drug delivery market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca (UK), 3M COMPANY (US), GlaxoSmithKline Plc. (UK), Novartis AG (UK), Pfizer, Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Becton Dickson & Company (US), Sanofi-Aventis (UK), Cadila Pharmaceuticals (India), Merck & Co. (US), and Aegis Therapeutics LLC (US), are some of the top players operating in the global nasal drug delivery market.